S&P 500   3,167.41 (+0.39%)
DOW   26,382.29 (+1.14%)
AAPL   382.82 (+0.24%)
MSFT   206.44 (-0.30%)
FB   236.62 (-1.00%)
GOOGL   1,503.26 (-0.59%)
AMZN   3,030.85 (-2.36%)
NVDA   406.34 (+1.06%)
GE   6.82 (+1.79%)
TSLA   1,516.49 (+1.30%)
DIS   118.05 (+1.56%)
BAC   23.74 (-1.90%)
S&P 500   3,167.41 (+0.39%)
DOW   26,382.29 (+1.14%)
AAPL   382.82 (+0.24%)
MSFT   206.44 (-0.30%)
FB   236.62 (-1.00%)
GOOGL   1,503.26 (-0.59%)
AMZN   3,030.85 (-2.36%)
NVDA   406.34 (+1.06%)
GE   6.82 (+1.79%)
TSLA   1,516.49 (+1.30%)
DIS   118.05 (+1.56%)
BAC   23.74 (-1.90%)
S&P 500   3,167.41 (+0.39%)
DOW   26,382.29 (+1.14%)
AAPL   382.82 (+0.24%)
MSFT   206.44 (-0.30%)
FB   236.62 (-1.00%)
GOOGL   1,503.26 (-0.59%)
AMZN   3,030.85 (-2.36%)
NVDA   406.34 (+1.06%)
GE   6.82 (+1.79%)
TSLA   1,516.49 (+1.30%)
DIS   118.05 (+1.56%)
BAC   23.74 (-1.90%)
S&P 500   3,167.41 (+0.39%)
DOW   26,382.29 (+1.14%)
AAPL   382.82 (+0.24%)
MSFT   206.44 (-0.30%)
FB   236.62 (-1.00%)
GOOGL   1,503.26 (-0.59%)
AMZN   3,030.85 (-2.36%)
NVDA   406.34 (+1.06%)
GE   6.82 (+1.79%)
TSLA   1,516.49 (+1.30%)
DIS   118.05 (+1.56%)
BAC   23.74 (-1.90%)
Log in

OTCMKTS:WILYYDEMANT A S/ADR Stock Price, Forecast & News

$14.15
+1.07 (+8.18 %)
(As of 07/14/2020 01:27 PM ET)
Add
Compare
Today's Range
$14.15
Now: $14.15
$14.15
50-Day Range
$13.08
MA: $13.83
$14.55
52-Week Range
$11.17
Now: $14.15
$14.55
Volume810 shs
Average Volume106 shs
Market Capitalization$6.81 billion
P/E Ratio31.44
Dividend YieldN/A
Beta0.16
Demant A/S, a hearing healthcare company, develops, manufactures, and sells products and equipment to enhance people's hearing in Europe, North America, the Pacific, Asia, and internationally. Its products include hearing devices and implants; diagnostic instruments; and personal communication systems, such as headsets and solutions for the professional call center and office market, as well as consumer headsets for the gaming and mobile segments. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.
Read More
DEMANT A S/ADR logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.76 out of 5 stars


Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:WILYY
Previous SymbolNASDAQ:WILYY
CUSIPN/A
CIKN/A
Phone45-3917-7300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.24 billion
Cash Flow$0.48 per share
Book Value$2.34 per share

Profitability

Miscellaneous

Employees15,837
Market Cap$6.81 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive WILYY News and Ratings via Email

Sign-up to receive the latest news and ratings for WILYY and its competitors with MarketBeat's FREE daily newsletter.

DEMANT A S/ADR (OTCMKTS:WILYY) Frequently Asked Questions

How has DEMANT A S/ADR's stock been impacted by COVID-19 (Coronavirus)?

DEMANT A S/ADR's stock was trading at $16.10 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, WILYY shares have decreased by 12.1% and is now trading at $14.15. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of DEMANT A S/ADR?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DEMANT A S/ADR in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for DEMANT A S/ADR.

Has DEMANT A S/ADR been receiving favorable news coverage?

Media coverage about WILYY stock has trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. DEMANT A S/ADR earned a coverage optimism score of 1.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about DEMANT A S/ADR.

Who are some of DEMANT A S/ADR's key competitors?

Who are DEMANT A S/ADR's key executives?

DEMANT A S/ADR's management team includes the following people:
  • Mr. Søren Nielsen, CEO, Pres & Member of Exec. Board (Age 49)
  • Mr. René Schneider, CFO & Member of Exec. Board (Age 46)
  • Mr. Søren Bergholt Andersson, VP of Investor Relations (Age 42)
  • Ms. Trine Kromann-Mikkelsen, VP of Corp. Communication & Relations
  • Mr. Jes Olsen, Pres of Oticon Medical

What is DEMANT A S/ADR's stock symbol?

DEMANT A S/ADR trades on the OTCMKTS under the ticker symbol "WILYY."

How do I buy shares of DEMANT A S/ADR?

Shares of WILYY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is DEMANT A S/ADR's stock price today?

One share of WILYY stock can currently be purchased for approximately $14.15.

How big of a company is DEMANT A S/ADR?

DEMANT A S/ADR has a market capitalization of $6.81 billion and generates $2.24 billion in revenue each year. The company earns $219.15 million in net income (profit) each year or $0.45 on an earnings per share basis. DEMANT A S/ADR employs 15,837 workers across the globe.

What is DEMANT A S/ADR's official website?

The official website for DEMANT A S/ADR is www.demant.com.

How can I contact DEMANT A S/ADR?

DEMANT A S/ADR's mailing address is Kongebakken 9, Smorum G7, 2765. The company can be reached via phone at 45-3917-7300 or via email at [email protected]

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.